Novo Nordisk’s Vice President for Clinical Data Operations and Insights Ibrahim Kamstrup-Akkaoui joins Richard this week for episode 4 of Season 3. As Ibrahim explains, the pace of innovation in clinical development is accelerating, sometimes generating billions of relevant data points for study teams to manage. AI is already adding value and can help organizations sustainably manage this growth. They discuss how to start small and think big with AI and concrete examples of where it is delivering for Novo Nordisk, such as generating meaningful test data and study builds. This discussion refl ..read more

Host: Richard Young, VP, Strategy, Veeva Vault CDMS Guest: Luis E. Torres, Head of Clinical Programming FSPx, Labcorp This week, Richard Young speaks to Luis E. Torres, head of Clinical Programming FSPx at LabCorp. They discuss how data managers can prepare for the future of clinical trials by adopting new technologies and skills to keep decentralized clinical teams connected. Richard and Luis share their thoughts on designing studies and processes that support end-user needs; the shifting goal posts of data cleanliness and database build expectations; and why data managers are uniquely positi ..read more

Pfizer’s Vice President for Data Monitoring and Management Demetris Zambas joins Richard in the hot seat and shares his fascinating journey through life sciences: from how his childhood experiences of receiving vaccines shaped his values to his contributions to our industry’s leading companies, and everything in between. They discuss the evolution of data science, the potential applications of AI, and whether we still need to strive for data perfection. Although the tools have changed, the mission and successful traits of a strong data scientist remain consistent — and could soon be enhanced ..read more

Pfizer’s Vice President for Data Monitoring and Management Demetris Zambas joins Richard in the hot seat and shares his fascinating journey through life sciences: from how his childhood experiences of receiving vaccines shaped his values to his contributions to our industry’s leading companies, and everything in between. They discuss the evolution of data science, the potential applications of AI, and whether we still need to strive for data perfection. Although the tools have changed, the mission and successful traits of a strong data scientist remain consistent — and could soon be enhanced ..read more

Nicole Raleigh hosts this special episode on-site from Boehringer Ingelheim’s Human Pharmacology Center in Biberach, Germany. Andrea Kloeble and Daniel Schwenk are part of the team reimagining drug development at Boehringer Ingelheim through the One Medicine Platform. They explain how their organization strives for medical excellence, and why exponential growth in study data volumes and sources requires a connected technology ecosystem. And Richard is in the guest seat this week to put this transformative initiative into industry context: as he explains, life sciences is no longer willing to a ..read more

We can think of no better way to kick off Season 3. In a deeply personal and moving episode, two patient advocates share their stories of working tirelessly to deliver a safe and effective gene therapy for children suffering from spastic paraplegia 50 (SPG50). After his infant son received a diagnosis of this ultrarare neurodegenerative disease in 2017, Terry Pirovolakis began a daunting four-year journey to find a breakthrough treatment that would help Michael and other affected children. We also hear from Samuela Bellini, who wants to bring this therapy to children in Italy. Their achieveme ..read more

This week, Richard Young speaks to Ken Getz, executive director and research professor at Tufts Center for the Study of Drug Development. Already well-known in our industry for his pioneering research on protocol design complexity and trial efficiency, Ken’s most recent study found that the average number of amendments per protocol increased by almost 60% over the past seven years. In this episode, Richard and Ken debate whether clinical research is striking the right balance in its approach to risk and innovation, the problem-solving role played by sites, and CISCRP’s work to improve public ..read more

In this episode, Richard Young speaks with Terttu Haring and Leonie Christianson from Syneos Health. Nowadays, clinical data managers have the tools to collect novel insights from large volumes of data. But has this influx of data and tech caused us to move farther away from the patients we serve? Together Terttu, Leonie, and Richard outline the major opportunities for life sciences organizations to put patients back at the heart of clinical strategy. Subscribe to State of Digital Clinical Trials, a Veeva podcast, to get new episodes as soon as they are released ..read more

In this episode, Richard Young speaks with Bayer’s Head of Clinical Trial Management Services and Solutions, Emma Earl. With over 20 years of experience, Emma is perfectly positioned to comment on the rapid transformation in clinical operations and what changes are coming up on the horizon. Together they outline the major opportunities and the missing ingredients for delivering efficient and patient-centric clinical trials. Subscribe to State of Digital Clinical Trials, a Veeva podcast, to get new episodes as soon as they are released ..read more

Host: Nicole Raleigh, Web Editor, Pharmaphorum Guest: Chris Moore, President, Veeva Europe We have a special episode for you this week! In a twist to our usual format, Nicole Raleigh of Pharmaphorum is in the host seat interviewing Veeva’s Chris Moore about his outlook on clinical trials in the U.K. and Europe. In a wide-ranging conversation, they cover the recent report from Lord O’Shaughnessy on U.K. life sciences, the impact of EU CTR, the potential and pitfalls of artificial intelligence, and what R&D organizations need next. Subscribe to State of Digital Clinical Trials, a Veeva pod ..read more